BIOHAUS

고객지원 자료실

자료실

엔큐라젠의 자료실 입니다.
[Eucuragen]PEG-BHD1028 Peptide Regulates Insulin Resistance and Fatty
작성자 : 관리자(manjo@encuragen.com)   작성일 : 21.04.01   조회수 : 19
첨부파일 : 엔큐라젠논문(2nd)_PEG-BHD1028 Peptide Regulates Insulin Resistance and Fatty.pdf

Article

 

PEG-BHD1028 Peptide Regulates Insulin Resistance and Fatty Acid β-Oxidation, and Mitochondrial Biogenesis by Binding to Two Heterogeneous Binding Sites of Adiponectin Receptors, AdipoR1 and AdiopR2

 

In Kyung Lee, Gyuyoup Kim, Do-Hwi Kim and Brian B. Kim

Abstract

 


Adiponectin plays multiple critical roles in modulating various physiological processes

by binding to its receptors. The functions of PEG-BHD1028, a potent novel peptid

agonist to AdipoRs, was evaluated using in vitro and in vivo models based on the

 

 

reported action spectrum of adiponectin. To confirm the design concept of

PEG-BHD1028, the binding sites and their affinities were analyzed using the SPR( Surface

 

 

Plasmon Resonance) assay. The results revealed that PEG-BHD1028 was bound to two

heterogeneous binding sites of AdipoR1 and AdipoR2 with a relatively high affinity. In

C2C12 cells, PEG-BHD1028 significantly activated AMPK and subsequent pathways and

 

enhanced fatty acid β-oxidation and mitochondrial biogenesis. Furthermore, it also

facilitated glucose uptake by lowering insulin resistance in insulin-resistant C2C12 cells.

PEG_BHD1028 significantly reduced the fasting plasma glucose level in db/db mice

following a single s.c. injection of 50, 100, and 200 ug/Kg and glucose tolerance at a

dose of 50 ug/Kg with significantly decreased insulin production.

The animals received 5, 25, and 50 ug/Kg of PEG-BHD1028 for 21days significantly lost their weight after 18days in a range of 5-7%.

These results imply the development of PEG_BHD1028 as a potential adiponectin replacement therapeutic agent.

 

*자세한 사항은 첨부파일 참고 부탁드립니다.*

 

 

 

 

 

 

 



이전글
다음글 [PLOS ONE] Discovery of a novel potent peptide agonist to adiponectin receptor 1